Prescient Therapeutics (FRA:UDD) Accumulated Depreciation: €-0.07 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Prescient Therapeutics Accumulated Depreciation?

Prescient Therapeutics FRA:UDD -4.69% Accumulated Depreciation is €-0.07 Mil as of Jun. 2026. The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Prescient Therapeutics's quarterly accumulated depreciation stayed the same from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil) but then increased from Dec. 2025 (€0.00 Mil) to Jun. 2026 (€-0.07 Mil).

Prescient Therapeutics's annual accumulated depreciation stayed the same from Jun. 2024 (€0.00 Mil) to Jun. 2025 (€0.00 Mil) but then increased from Jun. 2025 (€0.00 Mil) to Jun. 2026 (€-0.07 Mil).

Prescient Therapeutics Accumulated Depreciation Related Terms

Prescient Therapeutics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics Accumulated Depreciation Chart

Prescient Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.07

Prescient Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.07

Prescient Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of €-0.07 Mil mean?
Prescient Therapeutics (FRA:UDD) has a Accumulated Depreciation of €-0.07 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Prescient Therapeutics and its competitors.
Is Prescient Therapeutics' Accumulated Depreciation too high?
Prescient Therapeutics' current Accumulated Depreciation is €-0.07 Mil.
How does Prescient Therapeutics' Accumulated Depreciation compare to VRTX and REGN?
Prescient Therapeutics' Accumulated Depreciation of €-0.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current Accumulated Depreciation is €-0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current Accumulated Depreciation of €-0.07 Mil. The current Accumulated Depreciation is €-0.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current Accumulated Depreciation is €-0.07 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Other Exchanges PTX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.